910.5000 16.55 (1.85%)
NSE Mar 12, 2026 15:31 PM
Volume: 201.1K
 

910.50
1.85%
Geojit BNP Paribas
Strides reported its Q2FY22 revenue at Rs. 721cr, (4.8% QoQ, -9% YoY), enabled by a bounce back in the other regulated markets which was partially offset by an underperformance in the US markets. US markets (34% of total revenues) witnessed a 17% QoQ/-38% YoY...
Strides Pharma has gained 45.26% in the last 1 Year
More from Strides Pharma Science Ltd.
Recommended